Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Thursday's Bonus News Growth Picks: 3 Low-Cost Stocks That Could Double in ValueWritten by Chris Markoch. Published 10/27/2025. 
Key Points - Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks are objectively overvalued, which makes it difficult for investors to find opportunities with true upside potential. Penny stocks (i.e., shares trading below $5) are one place investors look, but they usually have a risk-reward profile suited only to nimble, risk-tolerant traders. There are still opportunities, though. One way to find them is to review analyst sentiment. Analysts don't always get it right, but they often have access to data and company resources that retail investors do not, so their perspectives are worth considering during due diligence. I'm Drew Day, founder of Base Camp Trading — and while I usually work behind the scenes, I wanted to personally share something special. My top income trader, Dave Aquino, has launched The Income Independence Initiative — a breakthrough program designed to help 100 regular investors pursue true income freedom. I was skeptical at first, but after seeing the real results his followers are already achieving, I knew we had to open it up. Click here to watch our kickoff interview and learn how to get started With that in mind, here are three stocks trading under $50 per share that analysts believe have meaningful upside. While none are guaranteed doubles, the consensus price targets are close enough that each could appreciate dramatically if the economy and company fundamentals cooperate. Equinox Gold: Gold's Momentum Could Keep Running Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold-mining company. As of Oct. 27, EQX is already up about 100% for the year. Analysts, however, put a consensus price target of $26 — implying more than 149% upside from current levels. Equinox is effectively a play on rising gold prices. Many analysts view mining stocks like EQX as the most direct way for equity investors to benefit from strength in the gold market. The most bullish forecasts even see spot gold reaching $5,000 before the end of 2025, with higher levels possible in 2026. Higher spot prices improve Equinox's mining margins and cash generation. The primary risk is a reversal in the gold rally. Still, institutional ownership of EQX is only about 38%, and that stake has been rising sharply over the past 12 months, suggesting growing professional interest. Birkenstock: A Consumer Stock Ready to Rebound Consumer discretionary names such as Birkenstock Group AG (NYSE: BIRK) have faced headwinds this year. BIRK is down about 25% in 2025, but the company may be unfairly grouped with a weak retail cohort despite solid underlying performance. Birkenstock is showing year-over-year revenue and earnings growth, with double-digit revenue gains across segments and channels. Analysts project earnings growth of more than 26% over the next 12 months, which aligns with a forward price-to-earnings (P/E) ratio near 23x. BIRK also has relatively high short interest — roughly 17% — though that figure has declined in the last month. A falling short interest could indicate that bears are losing conviction, and it still leaves the potential for a short squeeze if the stock rallies sharply. Analysts' consensus price target is $68.38, implying about 58% upside. Birkenstock reports third-quarter results on Dec. 17, and strong holiday sales could provide additional momentum into 2026. Immunocore: Biotech With Breakthrough Potential Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer therapies using T-cell technology. As of August 2025, the company has one drug that has successfully completed clinical trials and three candidates in or entering Phase 3 trials. Biotech stocks are often considered potential doubles because a single successful drug approval can transform a company's valuation. Immunocore is already generating measurable revenue and appears to be moving toward profitability, which reduces some of the binary risk typical of earlier-stage biotech names. Analysts set a consensus price target of $61 for IMCR, but opinions vary. HC Wainwright reiterated a Buy rating on Oct. 22 and assigned a $100 target, while Weiss Research has a Sell rating, arguing much of the stock's growth may already be priced in.
| 
